hEN1
Parkinson’s Disease
DiscoveryActive
Key Facts
About BrainEver
BrainEver is a clinical-stage biotech pioneering a novel therapeutic class based on homeoproteins—neuron maintenance and rejuvenation factors—to treat neurodegenerative diseases. The company's lead program, BREN02 (hEN1 for ALS), is in late preclinical development, supported by a recent €33M Series B financing to initiate a European clinical trial. With a pipeline spanning ALS, Parkinson's, and retinal disorders, BrainEver aims to deliver disease-modifying treatments by targeting the underlying biology of neuronal survival and function.
View full company profileTherapeutic Areas
Other Parkinson’s Disease Drugs
| Drug | Company | Phase |
|---|---|---|
| Dual A2A/H3 Antagonist | Palo BioFarma | Preclinical |
| FGF-based Therapeutic | Venturis Therapeutics | Pre-clinical |
| Blarcamesine (ANAVEX®2-73) | Anavex Life Sciences | Phase 2 |